title: A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.
abstract: BACKGROUND
  Statin combined with ezetimibe demonstrates significant benefit in lowering low density lipid cholesterol (LDL-C) and cardiovascular events abroad, but whether intermediate intensity statins combined with ezetimibe is superior to high-intensity statin monotherapy in Chinese people is unknown.
  
  
  METHODS
  A total of 125 patients were randomly assigned to a intermediate intensity rosuvastatin group (rosuvastatin 10mg/d, n=42), high-dose rosuvastatin group (rosuvastatin 20mg/d, n=41) or combination therapy group (ezetimibe 10mg/d and rosuvastatin 10mg/d, n=42) with a 12-week follow-up. The primary end point was the proportion of patients who achieved the 2011 ESC/EAS LDL-C goal <70mg/dL (1.8mmol/L) at week 12. Secondary end points included changes from baseline in lipids, the occurrence of all cardiovascular events, high-sensitivity C-reactive protein and safety markers.
  
  
  RESULTS
  The combination therapy group in the primary end point was significantly higher than rosuvastatin (20mg) and rosuvastatin (10mg) at week 12 (81.0% vs 68.3% vs 33.3%, P<0.001). And the similar change was observed in reducing LDL-C levels at week 12 (67.28% vs 52.80% vs 43.89%, P<0.001). The incidence of drug-related adverse events was much higher in the rosuvastatin 20mg group than the rosuvastatin 10mg group and the combination therapy group (17.0% vs 2.4% vs 4.8%, P<0.05).
  
  
  CONCLUSIONS
  The combination of rosuvastatin 10mg/ezetimibe 10mg was an effectively alternative therapy superior to rosuvastatin 20mg or 10mg with a greater effect on lowering LDL-C and a lower incidence of drug-related adverse events in Chinese patients.
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; The Department of Cardiology, The Pengzhou People's Hospital, Sichuan, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Ran
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Nie
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Yu-Lin
authors.initials: YL
authors.lastname: Gao
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Song-Bai
authors.initials: SB
authors.lastname: Deng
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Jian-Lin
authors.initials: JL
authors.lastname: Du
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Ya-Jie
authors.initials: YJ
authors.lastname: Liu
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Jing
authors.affiliation: The Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: qshe98@hotmail.com.
authors.forename: Qiang
authors.initials: Q
authors.lastname: She
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002097:C-Reactive Protein / Q000032:analysis; D002681:China / Q000453:epidemiology; D008078:Cholesterol, LDL / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000209:etiology; D004562:Electrocardiography / Q000379:methods; D000069438:Ezetimibe / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D000069438:Ezetimibe
keywords: Ezetimibe; Intensive lipid-lowering therapy; Rosuvastatin